Hunter syndrome (MPS II)
Rare disease · 2007–2007
2decisions
1medicine
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| idursulfase Treatment of Hunter syndrome (Mucopolysaccharidosis II, MPS II) where diagnosis is confirmed by documented deficiency of iduronate sulphatase enzyme activity. | Nov 2007 | Recommended | no section in document |
| idursulfase treatment of Hunter syndrome (MPS II) | Recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.